{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:34:39Z","timestamp":1793237679568,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jacadv.2026.102984","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:04:42Z","timestamp":1783695882000},"page":"102984","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Inflammatory, Cardiac, and Lipid-Related Biomarkers in Relation to Residual MACE Risk in the REPRIEVE Trial"],"prefix":"10.1016","volume":"5","author":[{"given":"Steven K.","family":"Grinspoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0660-4943","authenticated-orcid":false,"given":"Christopher","family":"DeFilippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Triin","family":"Umbleja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"McCallum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Christenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex B.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tricia H.","family":"Burdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"Aberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl J.","family":"Fichtenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald S.","family":"Bloomfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos D.","family":"Malvestutto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith S.","family":"Currier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4711-3956","authenticated-orcid":false,"given":"Markella V.","family":"Zanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9876-4049","authenticated-orcid":false,"given":"Pamela S.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Ribaudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2026.102984_bib1","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","article-title":"Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis","volume":"138","author":"Shah","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.102984_bib2","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1210\/jc.2006-2190","article-title":"Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease","volume":"92","author":"Triant","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacadv.2026.102984_bib3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to prevent cardiovascular disease in HIV infection","volume":"389","author":"Grinspoon","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102984_bib4","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1056\/NEJMc2400870","article-title":"Trial update of pitavastatin to prevent cardiovascular events in HIV infection","volume":"390","author":"Grinspoon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102984_bib5","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of Dyslipidemia","volume":"87","author":"Blumenthal Roger","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.102984_bib6","doi-asserted-by":"crossref","first-page":"e2114923","DOI":"10.1001\/jamanetworkopen.2021.14923","article-title":"Assessment of Coronary Artery Disease with computed tomography angiography and inflammatory and immune activation biomarkers among adults with HIV eligible for primary cardiovascular prevention","volume":"4","author":"Hoffmann","year":"2021","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.jacadv.2026.102984_bib7","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1016\/S2352-3018(24)00276-5","article-title":"Performance of the pooled cohort equations and D:A:D risk scores among individuals with HIV in a global cardiovascular disease prevention trial: a cohort study leveraging data from REPRIEVE","volume":"12","author":"Grinspoon","year":"2025","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jacadv.2026.102984_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ahj.2018.12.016","article-title":"Rationale and design of the randomized trial to prevent vascular events in HIV (REPRIEVE)","volume":"212","author":"Grinspoon","year":"2019","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacadv.2026.102984_bib9","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Goff","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.102984_bib10","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.102984_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.101781","article-title":"Coronary plaque, inflammation, subclinical myocardial injury, and major adverse cardiovascular events in the REPRIEVE substudy","volume":"4","author":"Lu","year":"2025","journal-title":"JACC Adv"},{"key":"10.1016\/j.jacadv.2026.102984_bib12","doi-asserted-by":"crossref","DOI":"10.1172\/JCI196021","article-title":"Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIV","volume":"135","author":"Kolossvary","year":"2025","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacadv.2026.102984_bib13","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/infdis\/jiw173","article-title":"Interleukin 6 is a stronger predictor of clinical events than high-sensitivity C-Reactive protein or D-Dimer during HIV infection","volume":"214","author":"Borges","year":"2016","journal-title":"The Journal of Infectious Diseases"},{"key":"10.1016\/j.jacadv.2026.102984_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.117461","article-title":"Comparison of interleukin-6 and high-sensitivity C-reactive protein for cardiovascular risk assessment: findings from the MESA study","volume":"390","author":"Ferreira","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacadv.2026.102984_bib15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.amjcard.2010.03.018","article-title":"Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for use of statins in prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)","volume":"106","author":"Ridker","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacadv.2026.102984_bib16","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa2405182","article-title":"Inflammation, cholesterol, Lipoprotein(a), and 30-year cardiovascular outcomes in women","volume":"391","author":"Ridker","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102984_bib17","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102984_bib18","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1161\/CIRCRESAHA.116.310527","article-title":"How common is residual inflammatory risk?","volume":"120","author":"Ridker","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.jacadv.2026.102984_bib19","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1161\/ATVBAHA.124.319980","article-title":"Novel therapeutics and upcoming clinical trials targeting inflammation in cardiovascular diseases","volume":"44","author":"Potere","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacadv.2026.102984_bib20","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jacc.2023.05.055","article-title":"Low-dose colchicine for secondary prevention of coronary artery disease: JACC review topic of the week","volume":"82","author":"Nelson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.102984_bib21","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1001\/jama.2024.5596","article-title":"Prognostic value of cardiovascular biomarkers in the population","volume":"331","author":"Neumann","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jacadv.2026.102984_bib22","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.amjmed.2017.07.033","article-title":"Using high-sensitivity cardiac troponin T for acute cardiac care","volume":"130","author":"Sandoval","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.jacadv.2026.102984_bib23","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1161\/ATVBAHA.116.308011","article-title":"Prevalence of Elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States","volume":"36","author":"Varvel","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacadv.2026.102984_bib24","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jacc.2023.12.031","article-title":"Lipoprotein(a) and major adverse cardiovascular events in patients with or without baseline atherosclerotic cardiovascular disease","volume":"83","author":"Berman","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.102984_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.117437","article-title":"Elevated lipoprotein(a) increases risk of subsequent Major Adverse Cardiovascular Events (MACE) and coronary revascularisation in incident ASCVD patients: a cohort study from the UK biobank","volume":"389","author":"Welsh","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacadv.2026.102984_bib26","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1186\/s12872-022-02932-y","article-title":"Effect of an increase in Lp(a) following statin therapy on cardiovascular prognosis in secondary prevention population of coronary artery disease","volume":"22","author":"Zhu","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jacadv.2026.102984_bib27","doi-asserted-by":"crossref","first-page":"847","DOI":"10.7326\/ANNALS-24-03564","article-title":"Statin therapy as primary prevention for persons with HIV: a synopsis of recommendations from the U.S. Department of Health and human services antiretroviral treatment guidelines panel","volume":"178","author":"Beavers","year":"2025","journal-title":"Ann Inter Med"},{"key":"10.1016\/j.jacadv.2026.102984_bib28","doi-asserted-by":"crossref","first-page":"e382","DOI":"10.1016\/S2352-3018(25)00047-5","article-title":"Statin use in HIV: european AIDS Clinical Society guidance for the primary prevention of cardiovascular disease","volume":"12","author":"Alagaratnam","year":"2025","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jacadv.2026.102984_bib29","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa1107477","article-title":"C-reactive protein, fibrinogen, and cardiovascular disease prediction","volume":"367","author":"Emerging Risk Factors Collaboration","year":"2012","journal-title":"N EnglJ Med"},{"key":"10.1016\/j.jacadv.2026.102984_bib30","doi-asserted-by":"crossref","first-page":"e248","DOI":"10.1093\/cid\/ciaf542","article-title":"Risk assessment in a global CVD prevention cohort of people with HIV by PCE, PREVENT, and SCORE2","volume":"82","author":"Grinspoon","year":"2026","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jacadv.2026.102984_bib31","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.109.192278","article-title":"Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association","volume":"119","author":"Hlatky","year":"2009","journal-title":"Circulation"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26004059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26004059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:26:47Z","timestamp":1793237207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X26004059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2772963X26004059"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102984","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammatory, Cardiac, and Lipid-Related Biomarkers in Relation to Residual MACE Risk in the REPRIEVE Trial","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102984","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102984"}}